Mergers have become one of the main survival strategies for global multinational pharmaceutical companies. In addition to buying new substances, companies are also making synergy, absorbing companies that own pipelines with high potential.

BMS is one representative example of such successful mergers. When the power of its portfolio declining with the patent expiration of blockbuster drugs such as 'Baraclude Tab.', the company decided to acquired Celgene, the company that owns ‘Revlimid,’ the drug that recorded the highest sales among prescription drugs at the time.

In addition to CAR-T therapy, Celgene owned various candidate substances in various areas including blood cancer. In addi